Tibotec and FDA Update Warnings for Intelence
Tibotec and FDA Update Warnings for Intelence August 27, 2009 Audience: Infectious disease healthcare professionals, patients. Tibotec Therapeutics and FDA notified healthcare professionals of revisions to the WARNINGS AND PRECAUTIONS section of the prescribing information for Intelence (etravirine). There have been postmarketing reports of cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme, as well as hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic